Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS >= 50%: Data from KEYNOTE-024-MedSci.cn

Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS >= 50%: Data from KEYNOTE-024

Brahmer, JR; Rodriguez-Abreu, D; Robinson, AG; Hui, RN; Csoszi, T; Fulop, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Deitz, AC; Lubiniecki, GM; Zhang, J; Rangwala, R; Reck, M

JOURNAL OF THORACIC ONCOLOGY, 2017; 12 (1): S8

科室
- - 订阅+
  - 更多科室
工具
服务